AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04739670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is platinum based chemotherapy drug
Study NCT05687773 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leap Motion Controller on flat display
Description: The LMC is a device with a Universal Serial Bus (USB) device capable of detecting the movement of hands and fingers. It is small in size and you need to connect the USB device to the computer and place your hands above the LMC. First, training will be carried out with the Leap Motion Controller instrument for 5 minutes, for a presentation and interaction with it, in the initial meeting. From the second meeting, the service protocol will be 16 sessions, this time being distributed as: first game lasting 7 minutes, second and third games lasting 6 minutes each and the last game lasting 8 minutes, totaling 27 minutes of intervention. Between games, about 2 minutes of rest was adopted. They were chosen through the website www.leapmotion.com¸ in order to relate them to the functional movements of the upper limbs in daily life tasks.
Study NCT05687773 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leap Motion Controller in Head-Mounted Display
Description: For the immersive group, the same equipment mentioned above Leap Motion Controller will be projected on the Head-Mounted Display model Oculus Quest 2 (Meta Platforms Inc.). The device has binocular displays with Fresnel lenses with a resolution of 1832 by 1920 pixels per eye. It is equipped with a Qualcomm Snapdragon XR2 processor with the refresh rate of 72hz - 120hz and 6GB of RAM. The equipment has a 90º field of view and approximately 500 grams of total weight. The treatment protocol and patient positioning will be the same as previously mentioned, except for the type of projection used. At the 2-minute rest interval between games, the HMD will be removed from the user to change the game in question, returning at the end of this period.
Study NCT06396169 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga Exercise
Description: Yoga Exercises
Study NCT06396169 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Calisthenic Exercise
Description: Calisthenic Exercises
Study NCT06062667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: accompany the birth
Description: Fathers will accompany their husbands during the birth process
Study NCT04186416 — intervention group
Intervention type: OTHER
Intervention: Mostcare® device
Description: The Moscare® system is connected to the patient monitoring devices. Data are collected just before and 5 minutes after the vascular filling.
Study NCT04186416 — intervention group
Intervention type: OTHER
Intervention: Transthoracic cardiac ultrasound
Description: Transthoracic cardiac ultrasound before and 3 minutes after the vascular filling.
Study NCT04790279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Initiation of amlodipine 2.5 mg
Study NCT04790279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NIFEdipine ER
Description: Initiation of nifedipine ER 30 mg
Study NCT04327362 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Participants will receive 20 min. of either sham or active tDCS prior to PE sessions using a 1 x 1 tDCS device with a ring electrode configuration that allows relatively excitatory and focal stimulation of the dorsomedial prefrontal cortex (dmPFC). Electrodes consist of sponges in a silicone rubber holder with a metal mesh conductor saturated with normal saline. A center anode (2.5 cm diameter) and a ring-shaped cathode (diameter inner/outer: 9.2/11.50 cm) will be centered over the dmPFC, with the anode placed the midline at 15% of the Fz to FPz distance. Active stimulation will commence with a 15 sec. ramping up period to target current (1.5 mA), followed by constant current for 20 min., and a 15 sec. ramping down period. For all sham sessions, stimulation will be immediately ramped down over a 15 sec. period following the initial ramping up period, and subsequently ramped up over 15 sec. prior to the final ramping down period.
Study NCT04327362 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Participants will receive 20 min. of either sham or active tDCS prior to PE sessions using a 1 x 1 tDCS device with a ring electrode configuration that allows relatively excitatory and focal stimulation of the dorsomedial prefrontal cortex (dmPFC). Electrodes consist of sponges in a silicone rubber holder with a metal mesh conductor saturated with normal saline. A center anode (2.5 cm diameter) and a ring-shaped cathode (diameter inner/outer: 9.2/11.50 cm) will be centered over the dmPFC, with the anode placed the midline at 15% of the Fz to FPz distance. Active stimulation will commence with a 15 sec. ramping up period to target current (1.5 mA), followed by constant current for 20 min., and a 15 sec. ramping down period. For all sham sessions, stimulation will be immediately ramped down over a 15 sec. period following the initial ramping up period, and subsequently ramped up over 15 sec. prior to the final ramping down period.
Study NCT04327362 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy
Description: All participants will receive 10 weekly sessions of standard Prolonged Exposure Therapy, or PE, which is a gold standard trauma-focused cognitive behavioral treatment for PTSD. The first sessions (1-2) predominately consist of psychoeducation about PTSD and the rationale for treatment, whereas subsequent sessions (3-10) consist of imaginal and in vivo exposure, involving repeated, prolonged, systematic, and deliberate practice approaching trauma reminders, as well as cognitive and emotional processing reactions to an index trauma memory.
Study NCT04327362 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure Therapy
Description: All participants will receive 10 weekly sessions of standard Prolonged Exposure Therapy, or PE, which is a gold standard trauma-focused cognitive behavioral treatment for PTSD. The first sessions (1-2) predominately consist of psychoeducation about PTSD and the rationale for treatment, whereas subsequent sessions (3-10) consist of imaginal and in vivo exposure, involving repeated, prolonged, systematic, and deliberate practice approaching trauma reminders, as well as cognitive and emotional processing reactions to an index trauma memory.
Study NCT04858815 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yogic breathing
Description: participation in yogic breathing
Study NCT06228573 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga program: In weeks 2-9, participants will attend twice weekly 1-hour sessions of yoga led by a certified yoga instructor trained in the intervention by collaborator Pearson. Videos will be provided for completion of home sessions. The yoga program is based on the Pain Care Aware certification program.38 Details of the program as well as the training of instructors are provided in the appendices. Briefly, classes will consist of 3 parts: centring and warming up aimed at regulating physiology prior to beginning the yoga postures; yoga postures and guided relaxation.
Study NCT06320678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing Students Education
Description: Effect of Concept Mapped Blended Learning Self-Directed Learning
Study NCT06275776 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ethicon Monocryl Smooth Suture
Description: Monocryl Smooth Suture 3-0 antibacterial with PS-2 needle. Monofilament suture, placed subcutaneously to approximate the superficial wound edges. Currently used in standard care.
Study NCT06275776 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ethicon Vicryl Rapide Braided Suture
Description: Vicryl Rapide Braided Suture 3-0 with FS-2 needle. Multifilament suture, placed subcutaneously to approximate the superficial wound edges. Currently used in standard care.
Study NCT06275776 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexifuze Indermil Topical Skin Adhesive
Description: Flexifuze Indermil Topical Skin Adhesive. The skin glue is applied after the application of the suture to further seal the wound from the external environment. Currently used in standard care.
Study NCT06275776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermabond Prineo Skin Closure System
Description: Dermabond Prineo Skin Closure System. Novel skin closure system consisting of a self-adhesive transparent mesh, over which skin glue is applied as well. This system approximates the wound edges, shields the wound from the external environment, enables healthcare professionals to still see the wound and surrounding tissue, and eliminates the invasive aspect of conventional sutures. Currently not used in standard care at the RHOC, but elsewhere it is being used.
Study NCT06275776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stryker Zip Skin Closure System
Description: Stryker Zip Skin Closure System. Novel skin closure system consisting of two self-adhesive strips placed parallel to either side of the wound. Zip tie/Cable tie-like structures running perpendicular to the adhesive strips can be tightened to approximate the wound edges and thusly close the wound. This system enables healthcare professionals to still see the wound and surrounding tissue, and eliminates the invasive aspect of conventional sutures. Currently not used in standard care at the RHOC, but elsewhere it is being used.
Study NCT06119971 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ACUPRESSURE
Description: Acupressure using disposable devices consisting of a metal microbead and an adhesive material.
Study NCT06119971 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUPRESSURE
Description: Acupressure using disposable devices consisting of a metal microbead and an adhesive material.
Study NCT04749628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabidiol
Description: Epidiolex (cannabidiol) oral solution
Study NCT06228573 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Yoga
Description: Yoga program: In weeks 2-9, participants will attend twice weekly 1-hour sessions of yoga led by a certified yoga instructor trained in the intervention by collaborator Pearson. Videos will be provided for completion of home sessions. The yoga program is based on the Pain Care Aware certification program.38 Details of the program as well as the training of instructors are provided in the appendices. Briefly, classes will consist of 3 parts: centring and warming up aimed at regulating physiology prior to beginning the yoga postures; yoga postures and guided relaxation.
Study NCT06025344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PanCytoVir™ 100 mg/mL oral suspension
Description: Single oral dose of 1000 mg (100 mg/mL) under fasted conditions
Study NCT05832385 — intervention group
Intervention type: RADIATION
Intervention: IMRT
Description: anal cancer: chemoradiotherapy, radiation dose>50Gy; rectal cancer: chemoradiotheray, radiation dose=50Gy
Study NCT04749628 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ora-sweet SF
Description: Ora-sweet SF placebo
Study NCT06025344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid 500 mg
Description: Single oral dose of 1000 mg under fasted conditions
Study NCT06097091 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-management education
Description: A self-management of the FM handbook will be provided. SME will be delivered via weekly video calls over a 6-week period. The video call lasting for 15 minutes, will consist of reviewing the weekly self-management content (5 min), questioning and answering related to the content of the self-management handbook (5 min), and a debriefing session (5 min).
Study NCT06097091 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pain neuroscience education
Description: Participants in the experimental group will receive a 6-week PNE program. The PNE program that is designed to explain pain to the participants will be implemented via 6 individual face-to-face sessions, each lasting for 45 minutes over a 6-week period. Printed take-home materials will be provided to the participants to enhance learning. The goal of PNE is to increase participants' knowledge about pain to help them reconceptualize their beliefs about pain and decrease perceived threats of pain. The content will be composed according to the second edition of the book, Explain Pain by Butler and Mosley (2013) as well as etiologies of fibromyalgia. Accordingly, the PI has developed the preliminary PNE content.
Study NCT05805826 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: C. difficile vaccine (previously studied formulation).
Description: Toxoid based Clostridioides difficile vaccine (previously studied formulation) given as an intramuscular injection
Study NCT05805826 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C. difficile vaccine formulation 1.
Description: C. difficile vaccine formulation 1 given as an intramuscular injection
Study NCT06002555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apraglutide
Description: Peptide analogue of GLP-2
Study NCT06002555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apraglutide
Description: Peptide analogue of GLP-2
Study NCT05805826 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C. difficile vaccine formulation 2.
Description: C. difficile vaccine formulation 2 given as an intramuscular injection
Study NCT05805826 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C. difficile vaccine formulation 3.
Description: C. difficile vaccine formulation 3 given as an intramuscular injection
Study NCT05805826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo.
Description: 0.9% sodium chloride solution given as an intramuscular injection
Study NCT05805826 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline Placebo.
Description: 0.9% sodium chloride solution given as an intramuscular injection
Study NCT06445647 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: core Stability exercise
Description: core stability exercise training
Study NCT06445647 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breathing exercises
Description: Deep breathing and diaphragmatic breathing exercises
Study NCT05357339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20% Albumin
Description: 100ml boluses 20% Albumin
Study NCT05357339 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloid
Description: 100ml bolus of crystalloid
Study NCT06426693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental feedback
Description: Participants provided with feedback of target brain activation patterns (e.g., thermometer) and will be instructed to try to change the feedback (e.g., decrease the thermometer).
Study NCT06426693 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control feedback
Description: Participants provided with control (sham, yoked to another participant) feedback (e.g., thermometer) and will be instructed to try to change the feedback (e.g., decrease the thermometer).
Study NCT05143593 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: results of SSBD are used to guide antibiotics adjustment
Description: secretions from low resipratory will be obtained on day1,day 3 and day7 after enrollment and detected by SSBD at bedside at once. Antibiotics will be adjusted on the results by experienced doctors.
Study NCT06370923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Distribution
Description: In intervention clusters investigators will identify initial distributors who will receive an HIVST kit for personal use and HIVST kits to distribute to local peers. These peers can subsequently become distributors, allowing the intervention to propagate through peer networks. A toll-free helpline will provide pre- and post-test support and an SMS-based risk assessment will expedite PrEP initiation at the clinic.
Study NCT06370923 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Health Worker Distribution
Description: Distribution of HIV self tests by community health workers
Study NCT05960643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training and application in breast modeling
Description: BSE application skill evaluation form will be evaluated out of 100 points. The form includes 7 skills: carefully reviewing the model, using three types of pressure, massage, hand position, performing three types of movement, examining each breast for five minutes, and detecting the nodule in the model. A high score is interpreted as a high level of skills.
Study NCT05960643 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: No intervention will be made against people in this group.
Study NCT05140876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: START mHealth Intervention
Description: The START mHealth intervention is a mobile application that will be downloaded by participants through their mobile phones. The application targets information, motivation, and behavioral skills relevant to ART adherence. Participants will have access to this application for 6 months.
Study NCT05819710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142
Description: Single dose of 5 mg of TS-142
Study NCT04259047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Regulation for Eyesight and Memory
Description: Participants randomized to DREAM will have 11 in-home visits over 2 years with a CHW, and 4 telehealth visits with a DM nurse educator.
Study NCT04259047 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Participants in this group will have 11 in-home CHW visits over 24 months to control for attention. During these visits, the CHW will provide general diabetes education. There will be no telehealth visits.
Study NCT05580003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07817883
Description: Oral suspension or solid oral formulation(s)
Study NCT05580003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo suspension
Study NCT05580003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo suspension
Study NCT05580003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: midazolam oral solution
Study NCT05580003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin 400 mg tablet
Study NCT05819710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142
Description: Single-dose of 10 mg of TS-142
Study NCT05683990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diamyd
Description: 4 μg (0.1 mL) of Diamyd administered 1 month apart.
Study NCT06539312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APP assessment and management of asthma
Description: APPs will be trained to follow NIH guidelines for assessment and management of asthma, and to apply their knowledge to the care of the students. Students will also receive DOT of the morning dose of their controller medication.
Study NCT06052332 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short course radiotherapy
Description: Patients will receive 5 daily fractions of radiotherapy. Each fraction will consist of 5 Gy for a total dose of 25 Gy.
Study NCT06052332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (optional)
Description: The choice of the adjuvant chemotherapy is to the investigator's discretion.
Study NCT06052332 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision
Description: Surgery must be performed according to the principles of total mesorectal excision. A watch \& wait approach is allowed for those subjects who have clinical complete response according to the local assessment.
Study NCT06052332 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total mesorectal excision
Description: Surgery must be performed according to the principles of total mesorectal excision. A watch \& wait approach is allowed for those subjects who have clinical complete response according to the local assessment.
Study NCT06052332 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Total neoadjuvant therapy
Description: The choice of the TNT is left to the investigator's discretion.~If RAPIDO:~* SCRT (5 fractions of 5 Gy), followed by~* Up to 18 weeks of oxaliplatin based chemotherapy (mFOLFOX6 or CAPOX)~If RAPIDO light:~* SCRT (5 fractions of 5 Gy), followed by~* Up to 12 weeks of oxaliplatin based chemotherapy (mFOLFOX6 or CAPOX)~If OPRA with induction chemotherapy:~* Up to 16 weeks of oxaliplatin-based chemotherapy (mFOLFOX6 or CAPOX), followed by~* CRT (25-28 fractions of 1.8-2.0 Gy each +/- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion ﬂuorouracil or capecitabine)~If OPRA with consolidation chemotherapy:~* CRT (25-28 fractions of 1.8-2.0 Gy each +/- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion ﬂuorouracil or capecitabine) followed by~* Up to 16 weeks of oxaliplatin-based chemotherapy (mFOLFOX6 or CAPOX)
Study NCT05819710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zopiclone
Description: Single-dose of 7.5 mg of zopiclone
Study NCT05819710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single-dose of placebo
Study NCT06053606 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryoablation of atrial fibrillation using only 28 mm size balloon
Description: all applications in all PVs are done with 28 mm balloon